Mark Sulkowski

47.6k citations
411 papers · 26.9k · 9 hit papers · h-index 72

Impact in

  • Hepatology top 0.01%
    • Hepatitis C virus research
    • Liver Disease and Transplantation
  • Epidemiology top 0.01%
    • Liver Disease Diagnosis and Treatment
    • Hepatitis B Virus Studies

Papers in

    • Hepatitis C virus research 357
    • Liver Disease and Transplantation 24
    • Liver Disease Diagnosis and Treatment 197
    • Hepatitis B Virus Studies 167

Mark Sulkowski

395 papers receiving 26.1k citations

Mark Sulkowski's Hit Papers

Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection 2017 · 504 citations
5040+8+17Years since publication10002.0k3.0k

Peers

Mark Sulkowski
Comparison fields: 5 of 157
  • Hepatology 22.5k
  • Epidemiology 20.6k
  • Infectious Diseases 6.2k
  • Virology 1.4k
  • Transplantation 629
Replace David L. Thomas with:
David L. Thomas United States
Stanislas Pol France
Raymond T. Chung United States
Thierry Poynard France
John G. McHutchison United States
Gregory J. Dore Australia
Eugene R. Schiff United States
K. Rajender Reddy United States
Jay H. Hoofnagle United States
Miriam J. Alter United States
Mark Sulkowski relative to David L. Thomas United States David L. Thomas's profile →
Citations per field
00.5×3.6×
David L. Thomas · 1×
Citations per year

Countries citing papers authored by Mark Sulkowski

Since Specialization
Citations

This map shows the geographic impact of Mark Sulkowski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Sulkowski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Sulkowski more than expected).

Fields of papers citing papers by Mark Sulkowski

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Sulkowski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Sulkowski. The network helps show where Mark Sulkowski may publish in the future.

Co-authors

The 25 scholars most cited alongside Mark Sulkowski, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mark Sulkowski Line = papers co-authored together Mark Sulkowski links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 411 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection†‡
Hit paper breakdown →
20063450
2
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance
Hit paper breakdown →
20092637
3
Boceprevir for Untreated Chronic HCV Genotype 1 Infection
Hit paper breakdown →
20111888
4
Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection
Hit paper breakdown →
2009889
5
Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 Infection
Hit paper breakdown →
2009803
6
Hepatotoxicity Associated With Antiretroviral Therapy in Adults Infected With Human Immunodeficiency Virus and the Role of Hepatitis C or B Virus Infection
Hit paper breakdown →
2000745
7
Response-Guided Telaprevir Combination Treatment for Hepatitis C Virus Infection
Hit paper breakdown →
2011566
8
Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection
Hit paper breakdown →
2017504
9 2002411
10
Retreatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin
Hit paper breakdown →
2014395
11 2002353
12 2002344
13 2010340
14 2003310
15 2015259
16 2007256
17 2007238
18
Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study1 1The other PROACTIVE Study Group investigators included the following: Vijayan Balan, M.D., Mayo Clinic Scottsdale, Scottsdale, Arizona; Norbert Bräu, M.D., Bronx VA Medical Center, Bronx, New York; Robert Brown, M.D., M.P.H., NY Presbyterian Medical Center, New York, New York; William Carey, M.D., Cleveland Clinic Foundation, Cleveland, Ohio; Andrea Duchini, M.D., Baylor College of Medicine, Houston, Texas; Greg Everson, M.D., University of Colorado Health Sciences Center, Denver, Colorado; Michael Fried, M.D., University of North Carolina, Chapel Hill, North Carolina; Robert Gish, M.D., California Pacific Medical Center, San Francisco, California; Ira Jacobson, M.D., Weill Medical College of Cornell University, New York, New York; John W. King, LSU Health Sciences Center, Shreveport, LA; Raymond Koff, M.D., University of Massachusetts Memorial Health Care, Worcester, Massachusetts; William Lee, M.D., University of Texas Southwestern Medical Center, Dallas, Texas; Mark A. Levstik, M.D., The University of Tennessee, Memphis, Tennessee; John G. McHutchison, M.D., Scripps Clinic, La Jolla, California; Marion Peters, M.D., University of California San Francisco, San Francisco, California; Kenneth Sherman, M.D., Ph.D., University of Cincinnati College of Medicine, Cincinnati, Ohio; Coleman Smith, M.D., Minnesota Clinical Research Center, St. Paul, MN; Ronald Wasserman, M.D., Hepatitis Resource Center, Walnut Creek, California.
2004232
19 2007228
20 2015218

About Mark Sulkowski

Mark Sulkowski is a scholar working on Hepatology, Epidemiology, Infectious Diseases, Rheumatology and Genetics, having authored 411 papers that have together received 26.9k indexed citations. Recurring topics across this work include Hepatitis C virus research (357 papers), Liver Disease Diagnosis and Treatment (197 papers), Hepatitis B Virus Studies (167 papers), HIV/AIDS drug development and treatment (100 papers), Systemic Lupus Erythematosus Research (41 papers), Chronic Lymphocytic Leukemia Research (32 papers), Liver Disease and Transplantation (24 papers) and HIV-related health complications and treatments (21 papers). The work is most often cited by research in Hepatology (22.5k citations), Epidemiology (20.6k citations), Infectious Diseases (6.2k citations), Virology (1.4k citations) and Transplantation (629 citations). Mark Sulkowski has collaborated with scholars based in United States, Germany and France. Frequent co-authors include David L. Thomas, John G. McHutchison, Andrew J. Muir, Richard K. Sterling, Ira M. Jacobson, Mark Nelson, Francesca J. Torriani, Ricard Solà, Doug Dieterich and Nathan Clumeck. Their work appears in journals such as Journal of Hepatology, Hepatology, Gastroenterology, Clinical Infectious Diseases and Journal of Viral Hepatitis.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact